Dementia
Conditions
Interventions
Performing PET imaging after administration of radiopharmaceuticals (approved drugs)
Sponsors
Takahashi Miwako
Yamaya Taiga
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who complained of subjective cognitive decline and was suspected to be in the early stages of Alzheimer's disease according to the symptoms. 2. Age at the time of informed consent is 40 to 80 years old, regardless of gender. 3. Patients who had a score of 24 points or higher on MMSE conducted within 6 months before consent was obtained. 4. Patients who are judged by the principal investigator to be capable of understanding the study explanation and consent document.
Exclusion criteria
Exclusion criteria: 1. History of hypersensitivity to alcohol. 2. History of serious complications, medical or surgery. 3. Patients currently taking medications; narcotics, psychotropic drugs, or anti-Parkinson's drugs. 4. Taking medications for diabetes mellitus. 5. Claustrophobia. 6. People who have difficulty undergoing head MRI due to tattoos (including tattoos and permanent makeup), pacemakers, cochlear implants, etc. 7.Patients who are pregnant or may be pregnant, or who are breastfeeding. 8.Patient who is judged to be inappropriate as a participant by the principal or collaborating doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Comparison of mean cortical SUVR of amyloid PET using a brain-dedicated PET and a whole-body PET 2. Characteristics of Abeta and FDG brain distribution in amyloid PET positive cases. | — |
Secondary
| Measure | Time frame |
|---|---|
| Abeta mean cortical SUVR by Amyloid PET, FDG SUV by FDG-PET for each brain region. | — |
Contacts
Public ContactMiwako Takahashi
National Institutes for Quantum Science and Technology
Outcome results
None listed